CLEVELAND, June 27, 2012 /PRNewswire/ -- D ATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced the launch of its D ATATRAK Accreditation Program (DAP). The D ATATRAK Accreditation Program empowers our user communities with the knowledge to use and leverage the D ATATRAK ONE™ unified, cloud-based clinical research platform to meet their individual needs and further their corporate initiatives.
Under the DAP, D ATATRAK's Clinical and Consulting Services group trains, accredits and supports our Connect Partners and enterprise users on the D ATATRAK ONE™ technology. Accreditation is achieved through a standardized training program, including the user's demonstration of a level of knowledge and expertise with each product implementation. Four D ATATRAK Connect Partners have already earned accreditation.
"The DAP provides our clients and partners with an industry-wide certification for bringing the D ATATRAK ONE™ design and deployment process in-house as well as recognizing members of our Connect Partner program to the rest of the industry as being certified to provide outstanding support services implementing the D ATATRAK ONE™ suite," stated Dr. Bill Gluck, VP D ATATRAK Clinical and Consulting Services. "This cost-effective implementation method enables our users to configure D ATATRAK's suite of products to most efficiently align with their or their customer's workflows and processes thus gaining the greatest value and benefits possible."
About D ATATRAK D ATATRAK International is a worldwide technology and services company delivering eClinical solutions and related services for the clinical trials industry. D ATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery via D ATATRAK's Clinical and Consulting Services™ group. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The D ATATRAK ONE™ software solution, deployed worldwide through an ASP or Enterprise Transfer offering, supports Phase I - Phase IV drug and devices studies in multiple languages throughout the world. D ATATRAK has offices located in Cleveland, Ohio; Bryan, Texas; and Cary (RTP), North Carolina. For more information, visit http://www.datatrak.net.Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain of the factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's report filed with the OTCQX Market on May 10, 2012 announcing its results for the three-month period ending March 31, 2012. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise. SOURCE DATATRAK International, Inc.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Check Out Our Best Services for Investors
Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.